CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion.

MLA

Boeri, Marco, et al. “CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Physician Preferences Trading off Benefits, Risks and Time to Infusion.” Future Oncology (London, England), vol. 17, no. 34, Dec. 2021, pp. 4697–709. EBSCOhost, https://doi.org/10.2217/fon-2021-0160.

APA

Boeri, M., Purdum, A. G., Sutphin, J., Hauber, B., & Kaye, J. A. (2021). CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risks and time to infusion. Future Oncology (London, England), 17(34), 4697–4709. https://doi.org/10.2217/fon-2021-0160

Chicago

Boeri, Marco, Anna G Purdum, Jessie Sutphin, Brett Hauber, and James A Kaye. 2021. “CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Physician Preferences Trading off Benefits, Risks and Time to Infusion.” Future Oncology (London, England) 17 (34): 4697–4709. doi:10.2217/fon-2021-0160.